Mitochondrial Problems and Changes in High Blood Pressure Heart Disease: Causes and New Findings

Mitochondrial fusion is the merging of two mitochondria into one, allowing mixing of contents (mtDNA, proteins, metabolites) between organelles. This process helps buffer stress by diluting damaged components and sharing metabolic intermediates. Mitochondrial fusion in mammals is mediated by large GTPases: mitofusin 1 and 2 (Mfn1/2) on the outer membrane, which tether two mitochondria together, and OPA1 on the inner membrane, which mediates inner membrane fusion and cristae remodeling [31,32,33]. In cardiomyocytes, Mfn2 also facilitates physical tethering between mitochondria and the endoplasmic reticulum, important for calcium signaling [34]. Proper fusion is required to maintain elongated, interconnected mitochondria capable of optimal oxidative phosphorylation [35]. If fusion is impaired (for example, by loss of Mfn2 or OPA1), mitochondria become overly fragmented, and cardiomyocytes can exhibit energy deficiency and heightened apoptosis susceptibility [36,37].

Mitochondrial fission is the division of one mitochondrion into two progenies. Fission serves to create new organelles (especially in dividing cells) and to isolate damaged regions of mitochondria that can then be removed by autophagy. The master regulator of fission is the dynamin-related protein 1 (Drp1), a cytosolic GTPase that is recruited to mitochondrial outer membrane sites marked by receptors such as Fis1, MFF, and MiD49/51 [38]. Drp1 forms helices that constrict and sever the mitochondria. In the heart, excessive activation of Drp1 has been linked to pathological fragmentation of mitochondria. Notably, fission is a double-edged sword: while moderate fission maintains healthy mitochondrial numbers and facilitates the removal of defective parts, excessive fission can lead to small, bioenergetically compromised mitochondria and can trigger apoptosis [39,40]. Mitochondrial dynamics regulate key cellular processes, including ATP generation, ROS production, calcium homeostasis, and apoptosis, underscoring why an imbalance in fission/fusion is detrimental.

Mitochondrial biogenesis is the process by which new mitochondria are formed, involving the growth and division of pre-existing mitochondria and the import of nuclear-encoded proteins. This process is orchestrated by transcriptional coactivator PGC-1α along with transcription factors such as NRF1/2 and estrogen-related receptors that induce the expression of mitochondrial proteins and of mitochondrial DNA replication factors like TFAM [41,42]. In the heart, biogenesis is upregulated during increased workload (exercise, thyroid hormone stimulation) to boost the organelle content and meet energy demands. Conversely, reduced biogenesis contributes to mitochondrial insufficiency in disease. For instance, hypertrophied hearts and aged hearts often show downregulation of PGC-1α and its downstream targets [43,44]. In spontaneously hypertensive rats (a genetic model of hypertension), left ventricular mitochondria have significantly lower PGC-1α levels, accompanied by depressed expression of regulators like sirtuin-1 and AMPK, which are normally protective and support biogenesis [43]. Thus, insufficient mitochondrial biogenesis in hypertension may exacerbate energy deficits.

Mitophagy is the selective autophagic degradation of damaged or superfluous mitochondria, a critical quality control mechanism. The best-characterized pathway is the PINK1/Parkin-mediated mitophagy. Under conditions of mitochondrial damage (e.g., loss of membrane potential), the kinase PINK1 accumulates on the outer membrane and recruits the E3 ubiquitin ligase Parkin from the cytosol. Parkin then ubiquitinates various outer membrane proteins, flagging the mitochondrion for enclosure by autophagosomes and degradation in lysosomes [45,46,47,48]. In the heart, basal mitophagy eliminates worn-out mitochondria, preventing accumulation of dysfunctional ROS-producing organelles [49,50]. Insufficient mitophagy can allow damaged mitochondria to persist and emit signals that cause inflammation or cell death [51]. Conversely, overly excessive mitophagy can deplete mitochondria and precipitate energy failure. Maintaining mitochondrial homeostasis requires coordinated biogenesis, dynamics, and mitophagy, with any imbalance potentially leading to disease. In cardiovascular disease including hypertension, evidence suggests mitophagy becomes dysregulated. For example, pressure overload-induced heart failure in mice is associated with reduced PINK1-Parkin mitophagy signaling, contributing to accumulation of defective mitochondria [52,53]. On the other hand, augmenting mitophagy has shown benefits in models of cardiac stress: one study found that enhancing Parkin-mediated mitophagy mitigated adverse remodeling after myocardial infarction, improving cardiac function [54]. In the context of hypertension, studies have implicated both PINK1/Parkin and receptor-mediated mitophagy pathways (e.g., BNIP3, FUNDC1) in hypertensive organ damage [55]. Notably, activating AMPK an energy-sensing kinase often suppressed in hypertension can stimulate protective mitophagy; AMPKα2 was shown to phosphorylate PINK1 and promote Parkin recruitment, preventing development of heart failure in a pressure-overload model [56] (see Figure 1).

Overall, the heart relies on efficient fusion to maintain mitochondrial function, fission to remove damaged parts, biogenesis to replenish the pool, and mitophagy to cull defective mitochondria. Hypertensive stress can disrupt each of these facets of mitochondrial dynamics, as discussed next. It is the interplay among these processes that determines whether a cardiomyocyte's mitochondria adapt to stress or succumb to dysfunction.

Chronic hypertension causes ultrastructural remodeling of cardiac mitochondria. Electron microscopy studies in hypertensive models and patients have documented hallmark changes such as mitochondrial swelling, loss or disorganization of cristae, and fragmentation of the mitochondrial network [1,57,58]. Mitochondrial volume density in cardiomyocytes can decrease due to both a drop in biogenesis and possibly activation of mitophagy as a stress response [3,59]. The remaining mitochondria are often enlarged ("megamitochondria") but paradoxically fewer in number, or sometimes abnormally small and fragmented, indicating a dysregulated fission/fusion balance. High blood pressure has also been associated with damage to cardiolipin, a phospholipid in the inner membrane that is critical for organizing cristae and respiratory chain supercomplexes [1,60]. Loss of cardiolipin impairs the structural integrity of cristae and the efficiency of electron transport. Together, these structural alterations—decreased mitochondrial number, swollen size, cristae remodeling or loss—have direct ramifications for function, as fewer and morphologically abnormal mitochondria produce less ATP and more ROS.

The hypertensive heart frequently exhibits reduced mitochondrial respiratory capacity. Isolated cardiac mitochondria from hypertensive animal models show depressed activities of electron transport chain (ETC) complexes and lower oxygen consumption rates (OCRs), a key parameter measured by Seahorse XF extracellular flux analysis [61,62] compared to normotensive controls [63,64]. The cristae abnormalities noted above (e.g., cristae rupture or simplification) likely underlie some of this respiratory inefficiency, because cristae architecture is crucial for optimal packing of ETC components. In a model of lipid overload simulating hypertension-related metabolic stress, cardiomyocytes exposed to palmitate displayed "abundant fragmented and lysed cristae" along with reduced expression of ETC complexes and a fragmented mitochondrial network [65]. This suggests that lipotoxicity (common in hypertensive patients with metabolic syndrome) can directly injure mitochondria, compounding the pressure overload stress.

Furthermore, mitochondrial oxidative phosphorylation substrates and preferences shift in hypertensive heart disease. As the myocardium hypertrophies and remodels, there is often a reversion to a more fetal metabolic profile increasing reliance on glucose and glycolysis and reduced fatty acid oxidation [66,67]. This shift, initially adaptive to maintain ATP production when mitochondria are impaired, eventually becomes maladaptive as it is less efficient in the adult heart. Indeed, in heart failure (frequently the end stage of HHD), metabolic substrate utilization changes contribute to mitochondrial dysfunction and impaired myocyte function. A chronically pressure-overloaded heart may have mitochondrial enzymatic deficiencies and altered expression of metabolic genes that prevent it from adequately using fatty acids, creating an energy-starved state despite plentiful fuel [68,69,70].

Mitochondrial dysfunction in HHD leads to excess generation of ROS, such as superoxide and hydrogen peroxide. Hypertrophy and pressure overload are associated with increased activity of NADPH oxidases and xanthine oxidase, which raise baseline oxidative stress and can damage mitochondria [71,72,73]. In turn, damaged mitochondria (with ETC electron leak or impaired antioxidant defenses) produce even more ROS, establishing a vicious cycle. High ROS can oxidize mitochondrial DNA, proteins, and lipids like cardiolipin, further impairing respiration. Oxidative modification of adenine nucleotide translocator or other inner membrane proteins can also trigger the mitochondrial permeability transition pore (mPTP) to open, causing collapse of the membrane potential and cell death [26]. Angiotensin II, a key hypertensive hormone, is known to stimulate mitochondrial ROS production in cardiomyocytes [74,75]. Excessive mitochondrial fission in this setting may exacerbate ROS release, because fragmented mitochondria tend to be less bioenergetically efficient and more prone to generating ROS per unit mass [57,76,77]. Elevated ROS not only directly injure cells but also act as signaling molecules that provoke pathological remodeling; for instance, ROS activate matrix metalloproteinases and pro-fibrotic gene programs, contributing to interstitial fibrosis in HHD [78,79,80].

Hypertensive stimuli can tilt the balance of mitochondrial dynamics toward fission. Angiotensin II has been shown to induce Drp1-mediated mitochondrial fission in cardiomyocytes, promoting cell death [81]. In one study, treating neonatal rat cardiomyocytes with Ang II increased Drp1 expression and mitochondrial fragmentation, while Drp1 inhibition (with the small molecule mdivi-1 or via gene silencing) attenuated the mitochondrial fission and protected the cells from hypertrophy and apoptosis [81]. In vivo, mice or rats subjected to Ang II infusion or pressure overload have demonstrated higher levels of active Drp1 and fragmented mitochondria in the myocardium, correlating with worse cardiac function. Conversely, genetic or pharmacological suppression of Drp1 can reduce hypertensive cardiac remodeling and dysfunction [81]. Mechanistically, Ang II triggers upstream signaling that impacts fission/fusion proteins; for example, Ang II was found to degrade the deacetylase Sirt1, leading to hyperacetylation of p53, which then upregulates Drp1 transcription, resulting in excessive fission and cardiomyocyte apoptosis [81]. This Sirt1-p53-Drp1 axis exemplifies how hypertensive signaling cascades can converge on mitochondrial dynamics pathways. On the fusion side, hypertension may reduce the expression of mitofusins and OPA1, or functionally impair them via post-translational modifications. Reduced Mfn2 in the heart has been reported under chronic stress, and OPA1 is sensitive to cleavage by OMA1, which is activated by mitochondrial membrane potential loss [57,82,83]. A consequence of fusion impairment is the loss of mitochondrial network connectivity and failure to compensate for localized damage, thereby compounding dysfunction. A summary of these disrupted dynamics is presented in Figure 2.

Proper turnover of mitochondria is necessary to remove those that are irreversibly damaged. Hypertension appears to dysregulate mitophagy in complex ways. Some studies suggest that hypertrophic hearts have insufficient mitophagy; for instance, a transverse aortic constriction (TAC) model of pressure overload showed a decline in PINK1-Parkin signaling and accumulation of damaged mitochondria, contributing to contractile dysfunction [53]. Consistently, cardiomyocyte-specific Parkin knockout mice develop exacerbated hypertensive cardiomyopathy, whereas Parkin overexpression or autophagy-enhancing treatments (like spermidine) can ameliorate cardiac hypertrophy and dysfunction in hypertension [55,84,85]. Spermidine, which stimulates autophagy/mitophagy, was found to prevent the progression of heart failure in salt-sensitive hypertensive rats, coincident with lowered blood pressure and regression of left ventricular hypertrophy [55,84,85]. These findings indicate that enhancing mitochondrial quality control can counteract some deleterious effects of hypertension on the heart. On the other hand, certain contexts might feature excessive mitophagy contributing to mitochondrial loss. A delicate balance is evident: for example, knockout of the mitophagy receptor BNIP3 in mice attenuates cardiac fibrosis and dysfunction in pressure overload, implying that unrestrained BNIP3-mediated mitophagy might worsen cell death [86,87]. Regional differences within the cell (perinuclear mitochondria might be turned over differently than subsarcolemmal ones) and temporal changes make this a complex picture. Nonetheless, a consistent theme is that failing hypertensive hearts often have an accumulation of abnormal mitochondria that the cell has failed to clear, indicating a relative insufficiency of effective mitophagy.

Hypertensive heart disease is typified by diastolic dysfunction, partly due to impaired calcium handling (e.g., reduced SERCA uptake, elevated diastolic Ca²⁺). Mitochondria in a hypertensive cardiomyocyte may experience chronically elevated calcium influx [88,89]. Excess matrix Ca²⁺ can precipitate the opening of the mitochondrial permeability transition pore. Once the mPTP opens persistently, the mitochondrion can no longer maintain its membrane potential, halting ATP synthesis and releasing pro-apoptotic factors. Even transient openings of mPTP (which can occur during calcium overload or oxidative stress) dissipate mitochondrial proton motive force and can contribute to arrhythmogenic events and contractile dysfunction. Normally, cyclophilin D and other components tightly regulate mPTP opening; however, oxidative stress and high Ca²⁺ in hypertension tilt the balance toward pore opening [90]. In parallel, decreased ATP output from sick mitochondria impairs the myocyte's ATP-dependent calcium pumps, worsening cytosolic Ca²⁺ control a feed-forward loop that damages both excitation–contraction coupling and mitochondria themselves. This pathological cycle of calcium dysregulation is illustrated in Figure 3.

Chronic inflammation is increasingly recognized in hypertensive heart disease and heart failure [14]. Mitochondrial dysfunction can be both a source and a consequence of inflammation. Damaged mitochondria may release danger-associated molecular patterns (DAMPs) such as mitochondrial DNA into the cytosol or circulation, which activate inflammatory pathways (e.g., via Toll-like receptors or the NLRP3 inflammasome). In hypertensive models, episodes of mitochondrial permeability transition and necrosis can incite sterile inflammation in the myocardium [91,92]. Conversely, cytokines and inflammatory cell infiltrates can produce nitric oxide and other factors that inhibit mitochondrial respiration and disrupt dynamics. Mitochondria-ER contact sites also appear to be altered in heart failure, affecting calcium and inflammatory signaling crosstalk [14]. The cumulative effect is a downward spiral where mitochondrial dysfunction and inflammation reinforce each other, leading to myocardial fibrosis and dysfunction [14].

In summary, hypertensive heart disease generates a convergence of damaging factors for mitochondria, such as structural damage to the organelles, suppressed biogenic renewal, imbalanced fission–fusion favoring fragmentation, defective removal of bad mitochondria, metabolic fuel shifts, and a high oxidative and calcium stress milieu. All these factors interconnect; for example, excessive fission yields fragmented mitochondria that produce more ROS, which in turn oxidize mitochondrial proteins and DNA, further lowering respiratory performance and signaling for cell death. Notably, many antihypertensive therapies (ACE inhibitors, beta-blockers) indirectly improve mitochondrial health by reducing the workload and neurohormonal drive on the heart [93,94]. However, these do not directly reverse mitochondrial damage. There is, therefore, considerable interest in mitochondria-targeted interventions for HHD. Antioxidants targeted to mitochondria (like mitoQ), agents that inhibit excessive fission (Drp1 inhibitors), or compounds that stimulate mitochondrial biogenesis (AMPK activators, PGC-1α agonists) are being explored in preclinical studies [95,96]. The goal of such therapies is to break the pathogenic cycle of mitochondrial dysfunction in the hypertensive heart and thereby halt or reverse cardiac remodeling.

Traditional 2D electron microscopy has long hinted at mitochondrial abnormalities in disease, but recent studies using three-dimensional electron microscopy techniques (such as serial block-face scanning EM and electron tomography) allow a far more quantitative and nuanced view. Vue et al. [12] performed 3D reconstructions of cardiac mitochondria in mice across the lifespan. This study was the first to quantify age-associated mitochondrial network changes in the heart, confirming a clear decline in mitochondrial volume and cristae structure with aging, as discussed. Extending this approach to disease, Vue and colleagues very recently applied 3D EM to failing human hearts [13]. In a 2023 bioRxiv preprint, they reported that human heart failure (with both ischemic and non-ischemic etiologies) is accompanied by distinct structural alterations in mitochondria and myofibrils [13]. Mitochondria from failing hearts showed shape changes and likely volume differences compared to non-failing donor hearts, while myofibrils in failing hearts had increased cross-sectional area and branching [13]. These structural perturbations were correlated with shifts in metabolomic and lipidomic profiles [13], suggesting that the physical disruption of mitochondrial architecture in heart failure might be mechanistically linked to metabolic remodeling. Although that study did not focus specifically on hypertensive heart disease, many heart failure patients have a history of hypertension; thus, the findings are relevant. They underscore how personalized structural phenotyping of mitochondria (e.g., identifying a patient's specific pattern of mitochondrial enlargement or loss) might guide tailored interventions in the future.

A breakthrough in fundamental mitochondrial biology came from a Nature Communications study by Katti et al. [11], which identified evolutionarily conserved regulators of muscle mitochondrial network organization. By leveraging Drosophila genetics, the study uncovered over 140 proteins associated with distinct muscle mitochondrial phenotypes (either tightly packed parallel networks or more reticular grid-like networks). Intriguingly, they showed that certain transcription factors, notably cut, salmon (salm), and H15, can independently regulate mitochondrial network configuration separate from muscle fiber type. For example, loss of salm converted the normally parallel mitochondrial networks in fly flight muscle into a grid-like arrangement akin to leg muscle, without changing the muscle's contractile protein type. These transcriptional regulators have mammalian homologs that may play roles in cardiac muscle. The implication is that the heart's mitochondrial network (which in healthy myocardium appears as a regular lattice of individual organelles between myofibrils) might be actively maintained by specific gene programs and in disease, these programs could be altered. While direct ties to hypertension are not yet made, one could speculate that hypertrophic signaling pathways might influence such network regulators. The concept of independent control of mitochondrial network geometry and content is a new paradigm; it means we might modulate how mitochondria are arranged and connected in heart cells without necessarily changing their number, potentially affecting efficiency and resilience. This is an area ripe for exploration in hypertensive models.

The MICOS has emerged as a critical player in cardiac mitochondrial integrity. As mentioned, Vue et al. [12] pointed to the MICOS decline in aging. In parallel, a 2023 study by Birker et al. revealed the importance of MICOS genes in heart development and disease [107]. This study was motivated by genetic findings in hypoplastic left heart syndrome (HLHS), a congenital defect, where variants in MICOS complex genes were implicated. Using Drosophila and mouse models, the researchers showed that partial loss of MICOS components (like CHCHD3/6, which are Mic19/Mic25 in the complex) in the heart led to drastically impaired contractility, sarcomere disarray, reduced ATP levels, and combined mitochondrial fission–fusion defects. In essence, MICOS disruption phenocopied severe cardiomyopathy. They further demonstrated that these effects were similar to knocking down ATP synthase subunits, underlining how cristae destabilization can depress energy production and muscle function. The same study also found that Opa1 (inner membrane fusion protein) interacts functionally with MICOS: Opa1 knockdown in fly hearts caused contractile dysfunction and arrhythmia, and combined Opa1+MICOS deficiencies worsened outcomes. The recognition that the MICOS complex is necessary to maintain cristae morphology and ATP production in heart mitochondria places an even greater emphasis on how cristae structure perturbations contribute to hypertensive heart disease. It is conceivable that chronic hypertensive stress or aging might downregulate MICOS components or alter their function (for instance, via post-translational modifications from ROS), leading to the cristae aberrations observed in HHD. Ongoing research is examining MICOS integrity in failing human hearts. From a therapeutic standpoint, stabilizing cristae structure (perhaps by preventing MICOS loss or enhancing OPA1 activity) might preserve mitochondrial function in hypertension.

Antentor Hinton Jr. and colleagues published a series of papers in 2023–2024 that deepen our understanding of mitochondria in cardiac disease. In a comprehensive 2024 Circulation Research review, Hinton's group emphasized how mitochondrial structural and functional changes contribute to human heart failure, and they spotlighted often-neglected factors such as mitochondria-ER contact sites and mitochondrial nanotunnels in cardiac pathology [14]. They note that mitochondrial morphology is closely linked to function, changing via dynamics to meet cellular energy needs, and that in heart failure, this relationship is perturbed. One intriguing phenomenon is the appearance of "donut-shaped" mitochondria and other unusual morphologies in stressed hearts. Although the significance of donut mitochondria (mitochondria that have folded into a torus-like shape) is not fully clear, they have been correlated with high oxidative stress and possibly represent an adaptive attempt to maintain membrane potential under stress [14]. Hinton's group also discusses how chronic inflammation in heart failure interacts with mitochondrial dysfunction, creating a cycle of damage [14]. This is particularly relevant to hypertensive heart failure, where low-grade inflammation often accompanies hypertension (due to vascular oxidative stress, etc.). Additionally, a 2024 study by Jenkins et al. (co-authored by Hinton) explores "mitochondria in disease: changes in shapes and communication," indicating a growing interest in how changes like increased mitochondrial networking or tunneling might occur in disease states [108]. These works collectively drive home that in conditions like HHD that progress to heart failure, we must consider not just classic bioenergetics, but also the organelle's social network how mitochondria interact with each other and with other organelles.

While not directly about hypertension, research on exercise offers relevant clues since exercise is known to enhance mitochondrial quality. Murach et al. [109] and others have studied how exercise training impacts muscle mitochondria, showing that physiological hypertrophy (from exercise) boosts mitochondrial biogenesis and respiratory function, in stark contrast to pathological hypertrophy from hypertension. For example, exercise triggers PGC-1α and NRF1 upregulation, increases mitochondrial content, and improves cristae density in the heart. These findings underscore that not all hypertrophy is equal; the molecular context (endocrine environment, hemodynamics) matters. The hope is to coax a pathological hypertrophied heart to adopt some of the mitochondrial benefits of exercise. Indeed, therapies like AMPK activators or PPAR agonists attempt to mimic aspects of the exercise response. Another angle is epigenetics: chronic hypertension can alter the expression of nuclear genes controlling mitochondria via DNA/histone modifications. Restoring youthful expression patterns of mitochondrial regulators (perhaps via deacetylase activators like SIRT1 agonists) may prove fruitful. A recent study in Aging Cell [110] showed that an 8-week treatment with the mitochondria-targeted peptide elamipretide in aged mice improved cardiac function (increasing cardiac strain and diastolic function) and skeletal muscle performance. Elamipretide aids mitochondrial electron transport and combats ROS. Interestingly, these functional gains occurred without changes in "tissue epigenetic or transcriptomic age," implying that even if the overall gene expression profile remains aged, directly supporting mitochondrial function pharmacologically can confer benefits. Extrapolating to HHD, such agents might improve an aged hypertensive heart's resilience.

Notably, sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs with proven mortality benefits in heart failure, have been increasingly linked to improved mitochondrial function. While their primary action is glycosuric, their cardioprotective effects are attributed to pleiotropic mechanisms, including a shift in myocardial fuel utilization towards ketones and a more efficient energy substrate, reduction in ventricular load, and direct improvements in mitochondrial bioenergetics and reduction of oxidative stress [111,112]. Their clinical success underscores the therapeutic principle of targeting metabolic and mitochondrial pathways in hypertensive heart failure, providing a strong rationale for developing next-generation, direct mitochondrial therapeutics.

Building on mechanistic insights, there have been experimental forays into drugs targeting dynamics. We mentioned mdivi-1 (a Drp1 inhibitor), which in rodent studies reduced Ang II-induced hypertension, cardiac hypertrophy, and fibrosis [113]. Another compound, SS-31 (also known as Bendavia, a mitochondrial-targeted peptide), has been shown to preserve cristae curvature and improve efficiency of oxidative phosphorylation; in models of hypertension or myocardial infarction, SS-31-treated animals had better cardiac function and less hypertrophy. Gene therapy or peptide delivery to boost OPA1 or mitofusin levels in the heart is being explored in preclinical models of heart failure, with promising results in normalizing mitochondrial structure. Furthermore, mitophagy enhancers like spermidine (which can be obtained through dietary supplementation) or urolithin A are under investigation for their cardioprotective effects in aging and hypertensive models. Cumulatively, these advances illustrate a translational trend: researchers are moving beyond correlative studies and actively testing interventions on mitochondrial targets a necessary step if we are to translate mitochondrial biology into treatments for hypertensive patients.

Finally, a noteworthy development is the improvement in diagnostic imaging and biomarkers for mitochondrial dysfunction. For instance, magnetic resonance spectroscopy can noninvasively measure cardiac phosphocreatine/ATP ratios, serving as a proxy for mitochondrial function in patients [114]. Hypertensive patients with heart failure have reduced ratios, and improvement in this metric correlates with therapy response. There is also growing interest in circulating mitochondrial DNA as a biomarker of cardiac stress. Hypertensive individuals show elevated cell-free mtDNA during acute hypertension episodes, reflecting tissue mitochondrial damage. As research progresses, we may see a panel of mitochondrial biomarkers used clinically to identify which hypertensive patients are at the highest risk of progressing to heart failure, thus prompting early aggressive therapy.

In summary, the recent few years have seen leaps in our understanding: from high-resolution mapping of mitochondrial changes (spatial and temporal), identification of new molecular players (MICOS, network regulators), to proof-of-concept therapies targeting mitochondrial dynamics. These advances paint a hopeful picture wherein, rather than viewing mitochondrial damage in HHD as an inexorable consequence, we might intervene to correct or mitigate it. The challenge moving forward is to integrate these findings into a cohesive strategy to treat or even prevent hypertensive heart disease by preserving mitochondrial health.